PolyPid Ltd.(PYPD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PYPD PolyPid Ltd.

Market Closed 12-20 16:00:00 EST

3.22

-0.28

-8.00%

盘后3.40

+0.18+5.59%

16:00 EST

High3.68	Low3.22	Vol32.75K
Open3.50	D1 Closing3.50	Amplitude13.14%
Mkt Cap21.91M	Tradable Cap11.59M	Total Shares6.80M
T/O116.17K	T/O Rate0.91%	Tradable Shares3.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PYPD","market":"US","secType":"STK","nameCN":"PolyPid Ltd.","latestPrice":3.22,"timestamp":1734728400000,"preClose":3.5,"halted":0,"volume":32751,"hourTrading":{"tag":"盘后","latestPrice":3.4,"preClose":3.22,"latestTime":"16:00 EST","volume":2,"amount":6.8,"timestamp":1734728401137},"delay":0,"floatShares":3599458,"shares":6803478,"eps":-6.021969,"marketStatus":"Market Closed","change":-0.28,"latestTime":"12-20 16:00:00 EST","open":3.5,"high":3.68,"low":3.22,"amount":116167.892968,"amplitude":0.131429,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.021969,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1593144000000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.5,"preClose":3.46,"latestTime":"09:25 EST","volume":106,"amount":353.999985,"timestamp":1734704700044},"postHourTrading":{"tag":"盘后","latestPrice":3.4,"preClose":3.22,"latestTime":"16:00 EST","volume":2,"amount":6.8,"timestamp":1734728401137},"volumeRatio":1.0911835090184927,"impliedVol":3.8487,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/PYPD","defaultTab":"news","newsList":[{"id":"2491766064","title":"PolyPid Price Target Maintained With a $14.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2491766064","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491766064?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:28","pubTimestamp":1734352080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PYPD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 07:28 ET (12:28 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYPD"],"gpt_icon":0},{"id":"2491466146","title":"PolyPid’s Strategic Advancements and Clinical Progress: A Buy Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2491466146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491466146?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:36","pubTimestamp":1734348963,"startTime":"0","endTime":"0","summary":"Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on PolyPid (PYPD – Research Report). The associated price target remains ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/polypids-strategic-advancements-and-clinical-progress-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/polypids-strategic-advancements-and-clinical-progress-a-buy-recommendation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","BK4007","BK4097","PYPD","PRGS"],"gpt_icon":0},{"id":"2490855108","title":"PolyPid announces research, development collaboration with ImmunoGenesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490855108?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:16","pubTimestamp":1733919414,"startTime":"0","endTime":"0","summary":"PolyPid (PYPD) announced a new research and development collaboration with ImmunoGenesis, a Houston-based clinical-stage biotechnology company deve...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polypid-announces-research-development-collaboration-with-immunogenesis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polypid-announces-research-development-collaboration-with-immunogenesis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PYPD","BK4007"],"gpt_icon":0},{"id":"2490853223","title":"PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490853223","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490853223?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA7MSRXZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PYPD"],"gpt_icon":0},{"id":"2490245855","title":"PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2490245855","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490245855?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918400,"startTime":"0","endTime":"0","summary":"PETACH TIKVA, Israel, Dec.  11, 2024  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/11/2995254/0/en/PolyPid-Announces-Research-and-Development-Collaboration-with-ImmunoGenesis-Leveraging-PLEX-Technology-to-Enhance-Cancer-Immunotherapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYPD","BK4007"],"gpt_icon":0},{"id":"2487595395","title":"PolyPid Faces Nasdaq Non-Compliance Challenge","url":"https://stock-news.laohu8.com/highlight/detail?id=2487595395","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487595395?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:28","pubTimestamp":1732904892,"startTime":"0","endTime":"0","summary":"PolyPid (PYPD) has released an update. PolyPid Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum stockholders’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polypid-faces-nasdaq-non-compliance-challenge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polypid-faces-nasdaq-non-compliance-challenge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SQQQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","PYPD","IE00B64PRP62.GBP","TQQQ",".IXIC","NDAQ","QID","BK4007","NQmain","BK4112","IE00B3QW5Z07.USD","MNQmain","LU2210149790.SGD","LU2095319765.USD","PSQ","QLD","BK4585","BK4588"],"gpt_icon":0},{"id":"2487593822","title":"BRIEF-Polypid Announces Receipt Of Nasdaq Notification Of Minimum Stockholders’ Equity Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2487593822","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487593822?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:17","pubTimestamp":1732904229,"startTime":"0","endTime":"0","summary":"BRIEF-Polypid Announces Receipt Of Nasdaq Notification Of Minimum Stockholders’ Equity Non-ComplianceNasdaq Inc NDAQ.O:POLYPID ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION OF MINIMUM STOCKHOLDERS’ EQUITY NON-COMPLIANCESource text: ID:nGNXl6wfRFurther company coverage: NDAQ.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUABKPKGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKPKM429.USD","LU2210149790.SGD","BK4007","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","PYPD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","BK4112","BK4585"],"gpt_icon":0},{"id":"2487593531","title":"PolyPid receives noncompliance notification from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2487593531","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487593531?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:10","pubTimestamp":1732903807,"startTime":"0","endTime":"0","summary":"PolyPid (PYPD) announced that it has received a written notification from the listing qualifications staff of Nasdaq notifying the company that it ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polypid-receives-noncompliance-notification-from-nasdaq-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polypid-receives-noncompliance-notification-from-nasdaq-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QID","SQQQ","IE00B3QW5Z07.USD","NQmain","LU2210149790.SGD","QLD","MNQmain","PSQ","IE00B64PRP62.GBP","LU2095319765.USD",".IXIC","BK4007","BK4112","IE00BGHQF748.EUR","PYPD","BK4585","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","TQQQ","NDAQ"],"gpt_icon":0},{"id":"2487598954","title":"PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2487598954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487598954?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nTUABKPKGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","IE00BKPKM429.USD","LU2210149790.SGD","BK4007","IE00B64PRP62.GBP","LU2095319765.USD","LU2210150020.SGD","PYPD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","BK4112","BK4585"],"gpt_icon":0},{"id":"2487959849","title":"PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2487959849","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487959849?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:05","pubTimestamp":1732903500,"startTime":"0","endTime":"0","summary":"PETACH TIKVA, Israel, Nov. 29, 2024  -- PolyPid Ltd.  , a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification  from the Listing Qualifications staff of The Nasdaq Stock Market LLC  notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550, due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated November 13, 2024, the Company reported stockholders' equity of approximately $2,158,000 as of September 30, 2024.PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX  technology pairs with Active Pharmaceutical Ingredients , enabling precise delivery of drugs at optimal release rates over durations ranging from several d","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/reEHAAw2X6GDWtgzw.4r1Q--~B/aD0zNjU7dz0zOTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8ff8dfae793300132d18fd5863b278b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/reEHAAw2X6GDWtgzw.4r1Q--~B/aD0zNjU7dz0zOTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8ff8dfae793300132d18fd5863b278b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polypid-announces-receipt-nasdaq-notification-180500305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","MNQmain","NQmain","BK4585","LU2095319765.USD","EQR","NDAQ","PSQ","PYPD","BK4007","SQQQ","LU2210150020.SGD","QLD","LU2210149790.SGD","BK4215","IE00BGHQF748.EUR","TQQQ","QID","BK4112",".IXIC","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2484645023","title":"PolyPid (PYPD) Gets a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2484645023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484645023?lang=en_us&edition=fundamental","pubTime":"2024-11-18 17:07","pubTimestamp":1731920845,"startTime":"0","endTime":"0","summary":"In a report released today, Balaji Prasad from Barclays maintained a Hold rating on PolyPid (PYPD – Research Report), with a price target of $10.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/polypid-pypd-gets-a-hold-from-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/polypid-pypd-gets-a-hold-from-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PYPD"],"gpt_icon":0},{"id":"2483834273","title":"Positive Indicators and Financial Stability Support Roy Buchanan’s Optimistic Outlook on PolyPid’s Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2483834273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483834273?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:55","pubTimestamp":1731599723,"startTime":"0","endTime":"0","summary":"Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on PolyPid (PYPD – Research Report). The associated price target remains th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-indicators-and-financial-stability-support-roy-buchanans-optimistic-outlook-on-polypids-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-indicators-and-financial-stability-support-roy-buchanans-optimistic-outlook-on-polypids-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PYPD","BK4007"],"gpt_icon":0},{"id":"2483848190","title":"PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848190","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483848190?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:08","pubTimestamp":1731568123,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.PolyPid Ltd  has achieved significant acceleration in patient enrollment for the Shield 2 pivotal trial, with approximately 550 subjects enrolled and 60 centers open globally.The company is operating from a position of financial strength, with funding secured beyond the upcoming interim analysis and into 2026 if all warrants are exercised.The Shield 1 trial results, which showed highly positive and statistically significant data, were published in the prestigious International Journal of Surgery.The company has ongoing discussions with strategic partners for the commercialization of DPLEX 100 in the US and other regions, indicating strong interest in the product's market potential.Research and development expenses increased significantly to $6 million, up from $3.8 million in the previous year, driven by the ramp-up in patient enrollment.The companys current cash balance is expected to f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polypid-ltd-pypd-q3-2024-070843063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PYPD"],"gpt_icon":0},{"id":"2483880376","title":"PolyPid Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483880376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483880376?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:25","pubTimestamp":1731511544,"startTime":"0","endTime":"0","summary":"PolyPid Ltd reports results for the quarter ended September 30 - Earnings SummaryPolyPid Ltd PYPD.OQ reported quarterly adjusted earnings of $1.22 per share for the quarter ended September 30, higher ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK21Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYPD"],"gpt_icon":0},{"id":"2483001061","title":"PolyPid Announces SHIELD II Trial Progress and Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483001061?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:32","pubTimestamp":1731501166,"startTime":"0","endTime":"0","summary":"PolyPid (PYPD) has released an update. PolyPid Ltd. has completed patient enrollment for the interim analysis of its SHIELD II Phase 3 trial, testi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polypid-announces-shield-ii-trial-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polypid-announces-shield-ii-trial-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4097","PYPD","PRGS","LU2065732104.USD"],"gpt_icon":0},{"id":"2483006935","title":"PolyPid Q3 2024 GAAP EPS $(1.22) Misses $(0.96) Estimate; Cash On Hand $9.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2483006935","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483006935?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:07","pubTimestamp":1731499646,"startTime":"0","endTime":"0","summary":"PolyPid (NASDAQ:PYPD) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.96) by 27.08 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41935024/polypid-q3-2024-gaap-eps-1-22-misses-0-96-estimate-cash-on-hand-9-5m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"PolyPid Q3 2024 GAAP EPS $(1.22) Misses $(0.96) Estimate; Cash On Hand $9.5M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYPD"],"gpt_icon":0},{"id":"2483900617","title":"PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483900617","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483900617?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"Last Patient Enrolled for Planned Unblinded Interim Analysisin Ongoing SHIELD II Phase 3 Trial ofD-PLEX100. SHIELD II Enrollment Completion Expected in December 2024 with Top-Line Results Anticipated in First Quarter of 2025. PETACH TIKVA,Israel, Nov. 13, 2024  -- PolyPid Ltd. , a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2024.Recently enrolled the last patient required  to conduct the planned unblinded interim analysis, which will occur during the current quarter, now that the 30-day follow-up assessment for the last patient has been completed. The unblinded interim analysis will lead to one of the following outcomes: early trial conclusion due to positive efficacy, continuation to planned patient recruitment , sample size re-assessment, or futility.“We are very encouraged by the recent significant acceleration in patient enrollment due to the open","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/reEHAAw2X6GDWtgzw.4r1Q--~B/aD0zNjU7dz0zOTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8ff8dfae793300132d18fd5863b278b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/reEHAAw2X6GDWtgzw.4r1Q--~B/aD0zNjU7dz0zOTU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8ff8dfae793300132d18fd5863b278b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polypid-provides-corporate-reports-third-120000289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PYPD"],"gpt_icon":0},{"id":"2482707515","title":"Sidoti Events, LLC's Virtual November Micro-Cap Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2482707515","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482707515?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:30","pubTimestamp":1731418200,"startTime":"0","endTime":"0","summary":"About Sidoti Events, LLC  and Sidoti & Company, LLC In 2023, Sidoti & Company, LLC  formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti's coverage universe comprises approximately 150 equities of which greater th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WM1Y3nX1YGcyl.b6Y7EaZQ--~B/aD0yNDE7dz05ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8c4614d356278d47c1f30ef4e5b87d5a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WM1Y3nX1YGcyl.b6Y7EaZQ--~B/aD0yNDE7dz05ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8c4614d356278d47c1f30ef4e5b87d5a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sidoti-events-llcs-virtual-november-133000213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRVO","GIFI","ZEUS","ALCO","SNCR","WINT","NGS","USEG","CVEO","CYRB","HYLN","MEC","RELL","PETS","ECRAF","ULY","BRLT","ATRA","HTCR","ZAPP","BK4229","TWIN","BEEP","BK4139","IRMD","BTTR","RAIL","BLGO","TRX","PRENW","PRE","OBIO","CRGOW","ZOM","PYPD","GAIA","OWLT","PERF","UJOGF","SEVCF","URG","NATR","CRGO","ANIX","LFVN","BK4156","SLVR","RZLV","VIOT","BETR","KLNG"],"gpt_icon":0},{"id":"2482073926","title":"PolyPid Ltd  expected to post a loss of 100 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482073926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482073926?lang=en_us&edition=fundamental","pubTime":"2024-11-11 23:38","pubTimestamp":1731339536,"startTime":"0","endTime":"0","summary":"PolyPid Ltd  expected to post a loss of100cents a share - Earnings Preview PolyPid Ltd PYPD.OQ PYPD.O is expected to show no change in quarterly revenue when it reports  results on November 13 for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nL8N3MI19T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYPD"],"gpt_icon":0},{"id":"2482456733","title":"PolyPid Announces $8.25 Million Share Sale Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2482456733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482456733?lang=en_us&edition=fundamental","pubTime":"2024-11-09 05:28","pubTimestamp":1731101310,"startTime":"0","endTime":"0","summary":"PolyPid (PYPD) has released an update. PolyPid Ltd., an Israeli company, is moving forward with a registration statement to sell up to $8.25 millio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polypid-announces-8-25-million-share-sale-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polypid-announces-8-25-million-share-sale-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PYPD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polypid.com","stockEarnings":[{"period":"1week","weight":0.2337},{"period":"1month","weight":-0.0774},{"period":"3month","weight":-0.0694},{"period":"6month","weight":-0.2441},{"period":"1year","weight":-0.1765},{"period":"ytd","weight":-0.1526}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.121115},{"month":2,"riseRate":0.25,"avgChangeRate":-0.045621},{"month":3,"riseRate":0.25,"avgChangeRate":-0.070738},{"month":4,"riseRate":0.5,"avgChangeRate":-0.03917},{"month":5,"riseRate":0.5,"avgChangeRate":0.003304},{"month":6,"riseRate":0,"avgChangeRate":-0.073234},{"month":7,"riseRate":0.2,"avgChangeRate":-0.081633},{"month":8,"riseRate":0.4,"avgChangeRate":0.005787},{"month":9,"riseRate":0,"avgChangeRate":-0.319775},{"month":10,"riseRate":0,"avgChangeRate":-0.101038},{"month":11,"riseRate":0.6,"avgChangeRate":0.027015},{"month":12,"riseRate":0,"avgChangeRate":-0.133529}],"exchange":"NASDAQ","name":"PolyPid Ltd.","nameEN":"PolyPid Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PolyPid Ltd.(PYPD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PolyPid Ltd.(PYPD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PolyPid Ltd.,PYPD,PolyPid Ltd.股票,PolyPid Ltd.股票老虎,PolyPid Ltd.股票老虎国际,PolyPid Ltd.行情,PolyPid Ltd.股票行情,PolyPid Ltd.股价,PolyPid Ltd.股市,PolyPid Ltd.股票价格,PolyPid Ltd.股票交易,PolyPid Ltd.股票购买,PolyPid Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PolyPid Ltd.(PYPD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PolyPid Ltd.(PYPD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}